Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
A 63-year-old woman was diagnosed with acute myelo-monocytic leukaemia, associated with MLL gene rearrangement, 16 months after completion of oral capecitabine for metastatic colon cancer. Capecitabine, recommended for use in metastatic breast and colon cancer and more recently as adjuvant treatment of colon cancer, has not previously been reported to be associated with secondary cancer.
Shapiro
Susan
S
Department of Haematology, West Middlesex University Hospital, Middlesex, UK.
Hughes
George
G
Al-Obaidi
Magda Jabbar
MJ
O'Reilly
Eamon
E
Ramesh
Subramanian
S
Smith
Jason
J
Ahmad
Riz
R
Dawson
Charlotte
C
Riddle
Pippa
P
Sekhar
Mallika
M
D000208:Acute Disease; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000556:secondary*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000473:pathology*
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil